Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2Phase 3 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

pembrolizumab 120Carboplatin 114Pemetrexed 74Cisplatin 71Nivolumab 68Paclitaxel 58Docetaxel 56Radiotherapy 41Erlotinib Hydrochloride 41Gemcitabine 35Etoposide 34atezolizumab 30osimertinib 29Cetuximab 27Ipilimumab 25Bevacizumab 25Radiosurgery 22durvalumab 21Cyclophosphamide 20Drug Therapy 18130-nm albumin-bound paclitaxel 17avelumab 14Taxes 14Gefitinib 14Albumin-Bound Paclitaxel 14Irinotecan 13Injections 13fludarabine 11Radiation 11cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × abivertinib × Thoracic × Clear all
NCT02330367 2021-09-10

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 1/2 Unknown
368 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02274337 2016-11-23

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Sun Yat-sen University

Phase 1/2 Unknown
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡